慶應義塾研究者情報データベース

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

• ライフサイエンス / 腫瘍診断、治療学 （放射線腫瘍学）

著書 【 表示 ／ 非表示 】

著書 【 表示 ／ 非表示 】

• Ablative Radiation Therapy for Early Hepatocellular Carcinoma

  Sanuki N., Takeda A., Tsurugai Y., Radiotherapy of Liver Cancer, 2021年01月

  　概要を見る

  Ablative radiation therapy, also known as stereotactic body radiation therapy (SBRT) or stereotactic ablative body radiotherapy (SABR), has an evolving role in the treatment of hepatocellular carcinoma (HCC), owing to recent advances in technology. SBRT is primarily used when other local therapies are not feasible. Although evidence is limited, SBRT has been demonstrated to be an effective treatment with excellent local control. In this chapter, we discuss the role of SBRT as a curative local therapy for patients with early HCC.

  • Access to Document (DOI)

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status

  Konishi T., Kumamaru H., Niikura N., Sagara Y., Miyashita M., Iwamoto T., Sanuki N., Tanakura K., Nagahashi M., Yoshida M., Kawashima M., Kinoshita T., Sasada S., Kinukawa N., Saji S., Ishida T., Taira N.

  Breast Cancer 32 （ 4 ） 621 - 629 2025年07月

  ISSN  13406868

  　概要を見る

  The Japanese Breast Cancer Society initiated the breast cancer registry in 1975 and migrated the registry to the National Clinical Database-Breast Cancer Registry (NCD-BCR) in 2012. This annual report presents 2021 data on the NCD-BCR. We analyzed data from 98,540 breast cancer (BC) cases registered in 2021. In 2021, 99.4% of BC cases were females with a median age of 61. Most (57.5%) were diagnosed at early stages (Stage 0 or I). Breast-conserving surgery was performed in 42.8% of cases. Sentinel lymph node biopsy was performed in 67.8%, followed by radiotherapy in 71.0% of those post-conserving surgery. Regarding postoperative systemic therapy, 63.1% received endocrine therapy, 28.2% received chemotherapy, and 14.9% received molecular-targeted therapy. ER positivity was observed in 75.2%, HER2 in 13.6%, and Ki67 ≥30% in 29.1% of cases. The median age of premenopausal cases was 46 (interquartile range, 42–49) years and the median BMI was 21.5 (19.7–24.2) kg/m² whereas the median age of postmenopausal cases was 69 (61–76) years and the median BMI was 23.0 (20.6–25.9) kg/m². In premenopausal cases, cases with normal BMI were more likely to be found at checkups without subjective symptoms and in the early stage than those with high BMI. The tendency of ER, PgR, HER2, and Ki67 status on BMI differed by menopause status; premenopausal cases with a lower BMI showed higher proportions of ER- and PgR-positive cancer and lower proportions of cancer with high Ki67. These nationwide descriptive statistics would help clinical explanation and further research on breast cancer.

  • Access to Document (DOI)

• Clinicopathological analysis of the absence of seminal vesicle invasion in prostate cancer patients without radiological evidence on magnetic resonance imaging

  Saihara K., Sanuki N., Hashimoto Y., Tochigi K., Hayakawa A., Tomioka S., Nara Y., Maruyama K.

  Reports of Practical Oncology and Radiotherapy 30 （ 2 ） 216 - 222 2025年04月

  ISSN  15071367

  　概要を見る

  Background: In definitive radiotherapy for localized prostate cancer, the seminal vesicle is included in the target volume for intermediate- and high-risk cases, though this increases the risk of toxicity to the bowel and rectum. This study retrospectively examined clinicopathological data to assess the absence of seminal vesicle invasion (SVI) in prostate cancer patients without radiological evidence of SVI using preoperative magnetic resonance imaging (MRI). Materials and methods: Patients with cT1c–cT3a prostate cancer who underwent radical prostatectomy between March 2010 and February 2024 were retrospectively selected, excluding those with distant metastasis, missing MRI data, preoperative systemic therapy, or delayed surgery post-biopsy. Preoperative risk factors [age, initial prostate-specific antigen (PSA), grade group (GG), clinical T stage, positive core ratio] and postoperative pathology were analyzed to assess SVI risk. The impact of GG changes between biopsy and postoperative pathology on risk classification and SVI treatment intensity in radiotherapy was also examined. Results: Of 368 patients, 308 met the inclusion criteria. SVI was observed in 26 patients (8.4%). Significant predictors of SVI included GG, initial PSA ≥ 8.6, and positive core ratio, with a positive core ratio < 0.5 and GG ≤ 3 indicating an SVI risk under 10%. GG discrepancies between biopsy and surgery were noted in 182 cases (59.1%), but had minimal impact on risk classification and SVI risk. Conclusions: Patients with a positive core ratio <0.5 had a low risk of SVI. GG discrepancies did not significantly underestimate prostate cancer risk, minimizing the risk of failing to treat true SVI.

  • Access to Document (DOI)

• A Case of a 12-cm Huge Hepatocellular Carcinoma Treated Successfully With Two-Stage CyberKnife Stereotactic Body Radiation Therapy.

  Nishimura S, Takeda A, Sanuki N, Kawase T, Tsukamoto N

  Cureus 17 （ 4 ） e83094 2025年04月

  ISSN  2168-8184

  • Access to Document (DOI)

• Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study)

  Sanuki N., Kimura T., Takeda A., Ariyoshi K., Oyamada S., Yamaguchi T., Tsurugai Y., Doi Y., Kokubo M., Imagumbai T., Katoh N., Eriguchi T., Ishikura S.

  International Journal of Radiation Oncology Biology Physics 121 （ 4 ） 942 - 950 2025年03月

  ISSN  03603016

  　概要を見る

  Purpose: To report final results of a prospective study of stereotactic body radiation therapy (SBRT) in patients with previously untreated solitary primary hepatocellular carcinoma (HCC). Methods and Materials: This prospective, single-arm, multicenter phase 2 trial recruited patients with HCC who were unsuitable for, or refused, surgery and radiofrequency ablation, with 3-year overall survival rates as the primary endpoint and survival outcomes and adverse events as secondary endpoints. The prescribed SBRT dose was 40 Gy in 5 fractions. The final data were analyzed in November 2022. Results: Between 2014 and 2018, 36 patients (median age, 73.5 years) were registered; enrollment was closed before full recruitment due to slow accrual. Overall, 34 patients were analyzed for efficacy evaluation after excluding 2 patients. The median tumor size was 2.3 cm. The median follow-up times for all patients and for survivors were 49 and 56 months, respectively. The 3-year overall survival rate was 82% (95% confidence interval, 65%-92%). The 3-year local control rate was 93% (95% confidence interval, 76%-98%). Grade 3 or higher SBRT-related nonlaboratory toxicities were observed in 4 patients (11%). No grade 5 adverse events were observed. Conclusions: Final results of this phase 2 trial suggest the efficacy and safety of SBRT for newly diagnosed early-stage HCC that is unfit for other local therapies. Although this study was underpowered by the small number of registrations, the excellent results indicate that SBRT may be an alternative option for the management of early-stage HCC.

  • Access to Document (DOI)

• Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression

  Nagahashi M., Kumamaru H., Kinukawa N., Iwamoto T., Kawashima M., Kinoshita T., Konishi T., Sagara Y., Sasada S., Saji S., Sanuki N., Tanakura K., Niikura N., Miyashita M., Yoshida M., Ishida T., Taira N.

  Breast Cancer 32 （ 2 ） 217 - 226 2025年03月

  ISSN  13406868

  　概要を見る

  This is an annual report by the Japanese Breast Cancer Society, which provides statistics on the clinical data on breast cancer in Japan, extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR). This report includes an update of 102,453 breast cancer cases at 1339 institutions registered in the NCD-BCR in 2022. Among the 101,793 female patients, the median age at cancer diagnosis was 62 years (interquartile range, 50–73 years), and 29.4% of the patients were premenopausal. Of these patients, 15,437 (15.2%) and 42,936 (42.2%) were diagnosed with stage 0 and I disease, respectively. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were positive in 78.7%, 69.4%, and 12.8% of the patients, respectively. Of the 97,154 patients without distant metastasis, 40,521 (41.7%) underwent breast-conserving surgery, and 5780 (5.9%) patients underwent some form of breast reconstruction procedures at the time of mastectomy. A total of 66,894 (68.9%) patients were treated with sentinel lymph node biopsy and 7155 (7.4%) patients were treated with sentinel lymph node biopsy followed by axillary node dissection. In the group of patients treated with breast-conserving surgery (n = 40,521), 29,500 (72.8%) received whole-breast irradiation. In the group of patients who underwent mastectomy (n = 54,476), 6226 (11.4%) received radiation therapy to the chest wall. Of the 13,950 patients receiving preoperative chemotherapy with or without molecular targeted therapy, 4308 (30.9%) achieved a pathological complete response, with the highest rate of 60.5% in patients with the hormone receptor-negative/HER2-positive subtype.

  • Access to Document (DOI)

全件表示 >>

総説・解説等 【 表示 ／ 非表示 】

総説・解説等 【 表示 ／ 非表示 】

• 高齢者に発症し,放射線治療が奏効した前額部脂腺癌の1例

  水野 彩加, 渡邊 清未, 津田 憲志郎, 小幡 康範, 佐貫 直子, 奈良 佳治

  日本皮膚科学会雑誌 （(公社)日本皮膚科学会）  135 （ 1 ） 128 - 128 2025年01月

  ISSN  0021-499X

• 【薬物療法の進歩における肝細胞癌の診断と治療Update】薬物療法の進歩における放射線治療の役割

  佐貫 直子, 木村 智樹, 斉原 和志, 武田 篤也

  肝臓クリニカルアップデート （医学図書出版(株)）  10 （ 2 ） 186 - 192 2024年10月

  ISSN  2189-4469

  　概要を見る

  近年の高精度放射線治療技術の進歩により,病変に高線量を照射しつつ肝実質への線量を低減することが可能となった。肝細胞癌のさまざまなステージで有効で安全な治療成績が報告されている。肝細胞癌にはさまざまな治療法があるが,放射線治療はとくに各治療の適応境界において一定の役割を果たし得る。複合免疫療法をはじめとした薬物療法が進歩したいま,改めて放射線治療を含めた局所治療の意義が問われるであろう。(著者抄録)

• 乳癌周術期治療の最適化　放射線腫瘍医からみた周術期放射線治療の最適化

  佐貫 直子, 水野 豊

  日本乳癌学会総会プログラム抄録集 （(一社)日本乳癌学会）  32回   19 - 19 2024年07月

• 領域リンパ節に対する適切な放射線療法　腋窩マネジメントの観点から

  佐貫 直子

  日本乳癌学会総会プログラム抄録集 （(一社)日本乳癌学会）  32回   49 - 49 2024年07月

• 完全独立型緩和ケア病院における地域基幹病院との放射線治療の連携

  渡部 秀樹, 海野 知美, 小原 和美, 村山 夏美, 安藤 真弓, 川口 リサ, 児玉 秀治, 佐貫 直子, 高田 彰憲, 南平 結衣, 間瀬 貴充, 野本 由人

  Palliative Care Research （(NPO)日本緩和医療学会）  18 （ Suppl. ） S396 - S396 2023年06月

全件表示 >>

競争的研究費の研究課題 【 表示 ／ 非表示 】

競争的研究費の研究課題 【 表示 ／ 非表示 】

• AYA世代乳癌に対する個別化放射線治療実現に向けた治療強度最適化指標の開発と応用

  2025年07月

  -

  2027年03月

  佐貫 直子, 研究活動スタート支援, 補助金,  研究代表者

担当授業科目 【 表示 ／ 非表示 】

担当授業科目 【 表示 ／ 非表示 】

• 放射線医学講義

  2025年度